Supernus Pharmaceuticals ... (SUPN)
31.59
-0.15 (-0.47%)
At close: Mar 04, 2025, 11:16 AM
Supernus Pharmaceuticals Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | FY07 |
| Revenue | 661.82M | 607.52M | 667.24M | 579.77M | 520.4M | 392.75M | 408.9M | 302.24M | 215M | 144.43M | 122.05M | 12.02M | 1.48M | 803K | 106K | 37.92M | 8.89M | 4.23M |
| Cost of Revenue | 77.91M | 83.78M | 87.22M | 75.06M | 52.46M | 16.66M | 15.36M | 15.21M | 11.99M | 8.42M | 5.76M | 1.1M | n/a | n/a | -13.4M | -8.59M | 336.00 | n/a |
| Gross Profit | 583.91M | 523.74M | 580.02M | 504.71M | 467.94M | 376.1M | 393.54M | 287.02M | 203.02M | 136M | 116.29M | 10.91M | 1.48M | 803K | 13.51M | 46.51M | 8.89M | 4.23M |
| Operating Income | 81.67M | -5.27M | 67.3M | 86.03M | 173.7M | 148.57M | 144.44M | 99.54M | 54.22M | 17.66M | 24.23M | -61.92M | -42.17M | -37.75M | -40.12M | 4.02M | -25.86M | -19.05M |
| Interest Income | 16.2M | 10.45M | 21.69M | 10.57M | 18.7M | 21.62M | 13.84M | 2.86M | 1.48M | 643K | 387K | 400K | 120K | 31K | 107K | 122K | 1.06M | 1.77M |
| Pretax Income | 97.87M | 2.77M | 60.74M | 73.17M | 168.65M | 147.49M | 140.18M | 100.62M | 50.37M | 14.97M | 19.87M | -92.27M | -46.28M | -39.47M | -39.47M | 4.14M | -33.48M | -17.27M |
| Net Income | 73.86M | 1.32M | 60.71M | 53.42M | 126.95M | 113.06M | 110.99M | 57.28M | 91.22M | 14.02M | 19.87M | -92.27M | -46.28M | 56M | -38.46M | 460K | -33.48M | -17.27M |
| Selling & General & Admin | 321.58M | 336.36M | 377.22M | 304.76M | 200.68M | 158.43M | 159.89M | 137.91M | 106.01M | 89.2M | 72.47M | 55.59M | 20.13M | 7.93M | 5.08M | 4.65M | 4.29M | 4.01M |
| Research & Development | 108.8M | 91.59M | 74.55M | 90.47M | 75.96M | 69.1M | 89.21M | 49.58M | 42.79M | 29.14M | 19.59M | 17.25M | 23.52M | 30.63M | 35.15M | 29.26M | 30.46M | 19.27M |
| Other Expenses | 71.87M | 101.06M | 82.63M | 29.99M | 15.7M | n/a | n/a | n/a | -15K | 38K | 39K | 101K | -660K | 117K | 542K | n/a | n/a | n/a |
| Operating Expenses | 502.25M | 529.01M | 534.4M | 425.21M | 292.34M | 227.52M | 249.1M | 187.48M | 148.8M | 118.34M | 92.06M | 72.83M | 43.65M | 38.55M | 40.23M | 33.91M | 34.75M | 23.28M |
| Interest Expense | n/a | 2.42M | 7.07M | 23.42M | 23.75M | 22.71M | 18.11M | 1.57M | 5.09M | 1.23M | 4.96M | 7.85M | 3.58M | 1.87M | 107K | 122K | 8.68M | 1.77M |
| Selling & Marketing Expenses | 227.29M | 99.7M | 267.79M | 199.71M | 134.75M | 40.8M | 43.3M | 33.8M | 21.9M | 19.3M | 14.8M | 14.6M | 5.8M | n/a | n/a | 94.00 | 499.00 | n/a |
| Cost & Expenses | 580.15M | 612.79M | 621.62M | 500.28M | 344.8M | 244.18M | 264.45M | 202.7M | 160.79M | 126.76M | 97.81M | 73.94M | 43.65M | 38.55M | 40.23M | 33.91M | 34.75M | 23.28M |
| Income Tax | 24M | 1.45M | 32K | 19.75M | 41.7M | 34.43M | 29.18M | 43.33M | -40.85M | 956K | 4.04M | 7.11M | 1.14M | -16.25M | -399K | 3.8M | 1.06M | 1.77M |
| Shares Outstanding (Basic) | 55.1M | 54.54M | 53.67M | 53.1M | 52.62M | 52.41M | 51.99M | 50.76M | 49.47M | 47.49M | 42.26M | 31.82M | 17.44M | 13.86M | 13.86M | 13.86M | 13.86M | 13.86M |
| Shares Outstanding (Diluted) | 55.96M | 55.51M | 61.68M | 54.36M | 53.69M | 53.82M | 54.1M | 53.3M | 51.71M | 51.16M | 50.58M | 31.85M | 17.44M | 13.86M | 13.86M | 13.86M | 13.86M | 13.86M |
| EPS (Basic) | 1.34 | 0.02 | 1.13 | 1.01 | 2.41 | 2.16 | 2.13 | 1.13 | 1.84 | 0.29 | 0.47 | -2.9 | -2.65 | 3.64 | -2.78 | -0.21 | -2.42 | -1.25 |
| EPS (Diluted) | 1.32 | 0.02 | 1.04 | 0.98 | 2.36 | 2.10 | 2.05 | 1.08 | 1.76 | 0.28 | 0.32 | -2.9 | -2.65 | 3.64 | -2.78 | -0.21 | -2.42 | -1.25 |
| EBITDA | 178.28M | 90.04M | 153.44M | 129.19M | 212.4M | 180.42M | 151.51M | 107.67M | 56.62M | 21.77M | -4.35M | -83.68M | -41.84M | -36.73M | -38.29M | 5.21M | -23.69M | -16.34M |
| Depreciation & Amortization | 80.41M | 84.86M | 85.63M | 32.59M | 20M | 10.22M | 7.06M | 8.13M | 2.4M | 921K | 928K | 742K | 871K | 879K | 1.19M | 1.07M | 1.11M | 932.21K |